Spinal cord compression in multiple myeloma: a single center experience

Jung, Hyun Ae; Cho, Soo Hee; Kim, Seok Jin; Jang, Jun Ho; Kim, Won Seog; Jung, Chul Won; Kım, Kihyun

doi:10.3109/10428194.2014.880429

Cited by 5 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spinal cord compression is a complication seen in 2-5% of all patients with cancer. MM constitutes 5-10% of all cancers associated with spinal cord compression (5). Treatment options for this cell dyscrasia include surgery, chemotherapy, and sometimes additional radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Omurilik Basısı Nedeniyle Dekompresyon Uygulanan Multipl Miyelom Olgularının Değerlendirilmesi

Eren¹,

Güleç²,

Güzey³

et al. 2020

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

Multiple myeloma accounts for 5-10% of all cancers associated with spinal cord compression. In this study, the surgical results of patients with multiple myeloma operated for spinal epidural compression were evaluated. Between 2011 and 2017, twenty-one patients were operated by posterior decompression for spinal cord compression, whose pathological diagnosis was multiple myeloma in our hospital's neurosurgery clinic included in the study. Demographic, clinical and radiological features of the patients and their status after surgery were examined. The mean age of the 21 patients was 62.6 ± 9.3. Thirteen patients were male and 8 were female. When the chain isotype was found in protein electrophoresis, the maximum IgG (52.4%) was present. The mean Karnofsky performance of the patients was 46.2 ± 17.7. Significant improvement was observed in the postoperative motor strength of the patients (p = 0.0001). In addition, postoperative pain-VAS scores-was significantly reduced (p = 0.0001). 90% of the patients were operated under emergency conditions. The number of patients who were operated stabilization with decompression was 5 (23.8%). When the radiological data were analyzed, the mean amount of compression in the operated vertebrae was 33.1% and the mean shrinkage rate of the tumor was 65.4%. Although spinal canal narrowing was observed in all patients, compression fracture was present in 16 patients (76.2%). The mean follow-up period was 22.3 months. During the follow-up period, 9 patients died, 5 of them were in the first year. Postoperative complications were wound infection in 2 patients, chronic renal failure in 1 patient and bilateral pleural effusion in 1 patient. Surgical treatment should be the first option if there is a progressive neurological deficit in patients with spinal cord compression due to multiple myeloma. With surgical treatment, decompression of the spinal cord compression, pain control and stabilization can be performed.

show abstract

Section: Discussionmentioning

confidence: 99%

Omurilik Basısı Nedeniyle Dekompresyon Uygulanan Multipl Miyelom Olgularının Değerlendirilmesi

Eren¹,

Güleç²,

Güzey³

et al. 2020

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…Previous findings have demonstrated that MM leads to 5-10% of all malignant tumors due to spinal cord compression (SCC) [16]. SCC is a devastating complication of MM and may lead to loss of neurological function.…”

Section: Spinal Cord Compressionmentioning

confidence: 99%

Treatment and Disease-related Complications in Multiple Myeloma

Kayyali¹,

Diak²,

Diak³

et al. 2023

Recent Updates on Multiple Myeloma

View full text Add to dashboard Cite

Multiple myeloma is a clonal plasma cell neoplasm that is mainly characterized by anemia, renal insufficiency, hypercalcemia, and bone destruction. Since 1990, there is an increase in the incidence of myeloma globally by 126%. However, due to the presence of the new therapeutic agents such as proteasome inhibitors, immunomodulatory drugs, Chimeric antigen receptor T-cell therapy, bispecific antibodies, bisphosphonates, corticosteroids, melfulfen, iberdomide, cyclophosphamide, plerixafor, melphalan chemotherapy, nuclear transport inhibitor, and monoclonal antibodies, as well as upfront autologous and allogeneic hematopoietic cell transplantation in eligible patients, a decline in the age-standardized mortality rate has been seen. This leads to higher survival rates of patients with multiple myeloma in the last 15 years, and hence, patients with multiple myeloma for 10–15 years are no longer rare. However, it has been observed that even though the treatment goal was to prevent end-organ damage, improve or maintain quality of life (QoL), and achieve long-term disease-free survival; thus, new treatments have converted myeloma into a chronic disease, such as peripheral neuropathy (PN), venous thromboembolism, and cardiac toxicity. Notably, most patients remain on continuous treatment for extended time periods, which leads to various complications. Hence, management of immediate and late complications from disease and treatment is a critical component of survivorship care in myeloma.

show abstract